Maridebart cafraglutide
Experimental medication
From Wikipedia, the free encyclopedia
Maridebart cafraglutide (also known as MariTide;[1] developmental name AMG 133) is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor (GLP-1R) and an antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). Namely, MariTide consists of a monoclonal antibody against GIPR conjugated to two peptidic GLP-1R agonist molecules via amino acid linkers.[2] In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.[3][4][5]
| Clinical data | |
|---|---|
| Other names | AMG 133 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| UNII | |
| ChEMBL | |
